kaal:position:2026-07-31-1102

Age, Experience, and NMDA Antagonism: Dynamic Regulation of Parvalbumin Expression in Normal and Chronically Ketamine-Treated Rats should be assessed against Kaal's source-bound claim that Ex post trial and error rulemaking requires as a precondition that information about optimized rule requirements becomes available, and in an age of exponential innovation that information may never materialize or may arrive too late for the method to work. The current metadata indicates a plausible connection through dynamic regulation, but the defensible response is a qualification until the source text confirms agreement, scope, methods, and limitations.

Affirmed commentary position. This record extends a source-bound scholarly claim but is not a verbatim paper claim.

Holds when

exponential rates of innovation
External evidence level: metadata only.
Mapping review tier: moderate-confidence claim review.
The literature-to-claim mapping remains explicitly ambiguous and should not be treated as a settled equivalence.

Current debate

Age, Experience, and NMDA Antagonism: Dynamic Regulation of Parvalbumin Expression in Normal and Chronically Ketamine-Treated Rats

Scholarly basis

kaal:claim:2740477-016
Wulf A. Kaal, Erik P.M. Vermeulen, Venture Capital as Dynamic Regulation of Disruptive Innovation (2016). SSRN: https://ssrn.com/abstract=2740477
Source PDF sha256: c72871b76fa2ad5a8a69ee8d3defc8f64e624be9052ce763e79cf6c58883f726

Evidence and mapping

Evidence: metadata only
Review tier: moderate-confidence claim review
Mapping confidence: 0.3576
Mapping ambiguous: true

Topics

dynamic-regulationregulatory-failure

Provenance

Affirmed in historical-backfill:2026-07-31:phase-0005 on 2026-07-31. Review record.

Verify

Canonical markdown sha256: 1c2d2e8734e8de131971766fc21fb7f02f04d5200846c4b09f55ae7d6e09aae2
curl -s https://wulfkaal.github.io/positions/2026-07-31-1102.md | sha256sum